Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma

Launched by SUN YAT-SEN UNIVERSITY · Oct 2, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at how effective three cycles of chemotherapy, known as CEV, are for treating high-risk retinoblastoma in children who have had one eye removed (a procedure called enucleation). The study focuses on patients with Stage I retinoblastoma, which is an early stage of this eye cancer, to see if this treatment can help improve their outcomes after surgery.

To participate in the trial, children must have a confirmed diagnosis of retinoblastoma, have undergone enucleation of the affected eye, and be able to provide consent for the study. They must not have any previous treatments for retinoblastoma in the study eye or have participated in other clinical trials recently. If eligible, participants will receive the chemotherapy and will be monitored closely throughout the study to track their progress and any side effects. This trial is currently recruiting participants of all ages and genders, aiming to improve treatments for this serious condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to provide written informed consent and comply with study assessments for the full duration of the study.
• • Definite pathology signs of retinoblastoma, Stage I base on International Retinoblastoma Staging System.
• • Received enucleation in the study eye.
• • Monocular retinoblastoma.
• Exclusion Criteria:
• • Any previous disease in the study eye.
• • Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding vitamins and minerals).
• • History of chemical intervention for retinoblastoma in the study eye.